Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) after starting CRENESSITY CRENESSITY reduces excess